Glide Pharma (Abingdon, UK) has signed an agreement with Nypro Healthcare (Clinton, MA, USA) to complete the design optimisation of its solid-dose needle-free injection device. The Glide SDI pushes a tiny solid dosage into the skin, where it dissolves and releases medication, by means of a handheld spring-powered device. Nypro will apply its expertise to optimising device design for manufacturing scale up.
Glide Pharma will commercialise its device within a sector that is growing at a 12.7% compounded annual rate. According to a report from marketsandmarkets.com, the European injectable drug-delivery market will be worth €9.5 billion by 2017, compared with €5.2 billion in 2012. Growth drivers include improved reimbursement prospects and technical advances.
The global market for injectable drug delivery is expected to reach €33.2 billion by 2017.
Related content:Norbert Sparrow